MONTREAL, April 3, 2014 /CNW Telbec/ - At the 6th Annual National Conference to Defeat Cancer, organized by Coalition
Priorité Cancer, Merck Canada reinforced the company's continued
commitment to the Quebec life sciences research innovation sector by
announcing a $2-million grant to the Quebec - Consortium de recherche
en oncologie clinique (Q-CROC).
The grant received by Q-CROC will go towards biomarker-driven clinical
research for personalized medicine in cancer, notably in the framework
of a public-private partnership put forward by Q-CROC and the
newly-formed Centre of Excellence PreThera Research.
"Oncology is a priority area for Merck and we are dedicated to bringing
forward innovations that can make a meaningful difference in the lives
of patients with cancer", said Dr. Thomas R. Cannell, President and
Managing Director, Merck Canada Inc. "This $2-million grant to Q-CROC
will support patient-centered research in Québec and ultimately may
help bring about advances in oncology care."
"This important contribution further solidifies our position as a
provincial interface for clinical research to help bridge the gap
between industry, government, healthcare establishments and the
research community in Quebec. The grant from Merck Canada will allow us
to get closer to our ultimate goal of providing cancer patients in Quebec with access to the most advanced and personalized medicine," said Dr. Gerald Batist, co-founder of Q-CROC and Director of the
Segal Cancer Centre, Jewish General Hospital.
Merck's investment in Quebec
This announcement marks the latest contribution by Merck towards its
commitment to provide $100 million over five years in biopharmaceutical
R&D in Quebec. Today's announcement brings Merck's total contributions
to approximately $86 million.
Note: All amounts expressed in this press release are in Canadian
dollars unless otherwise noted.
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our medicines, vaccines, biologic therapies, and consumer and
animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. For more information about our
operations in Canada, visit www.merck.ca.
About the Quebec - Clinical Research Organization in Cancer (Q-CROC)
The Q-CROC is a provincial interface for clinical research, bridging the
gap between industry, government, healthcare establishments and the
research community. To address the increasingly competitive landscape
for clinical research, the Q-CROC facilitates an environment for
sharing knowledge, needs and strengths, thereby enticing the conduct of
studies in the province and providing patients with access to new
innovative treatments. Complementary to this activity, the Q-CROC
provides a niche of expertise in the discovery and validation of
biomarkers to predict the response or resistance to treatment. By these
engagements, the Q-CROC aims to position the province of Québec at the
national and international forefront of personalized medicine in
cancer, so that patients can access the most cutting-edge treatments.
For more information about Q-CROC, please visit www.qcroc.ca.
About PreThera Research
The Business-Led Network of Centres of Excellence in Precision
Therapeutics (PreThera Research) will help develop cancer treatments
that are increasingly personalized for patients by combining the latest
discoveries in cancer biology with new approaches to clinical trials.
The network's research program will take advantage of the current
understanding that almost all tumours can be divided into smaller
groups with a unique biomarker - a molecular signature that can be
targeted by a specific drug. Using a growing database that identifies
these biomarkers and the patients that have them, PreThera Research
will make it possible to accelerate the identification of innovative
new drugs and bring them to the medical field. This will be
accomplished by identifying patients that are most likely to respond to
a precise treatment for their greater benefit and that of the Life
Science Industry and the health care system. www.prethera.ca
The news release is available at www.cnw.ca.
Forward Looking Statement
This news release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck's management and are
subject to significant risks and uncertainties. There can be no
guarantees with respect to pipeline products that the products will
receive the necessary regulatory approvals or that they will prove to
be commercially successful. If underlying assumptions prove inaccurate
or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck's ability
to accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
Merck's patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can
be found in Merck's 2013 Annual Report on Form 10-K and the company's
other filings with the Securities and Exchange Commission (SEC)
available at the SEC's Internet site (www.sec.gov).
Image with caption: "Ms. Jennifer Chan, Vice-President, Policy & Communications, Merck Canada Inc., Ms. Nathalie Rodrigue, President, Coalition Priorité Cancer, and Dr. Thérèse Gagnon-Kugler, Ph. D., President and General Director, PreThera, and General Director, Q-CROC. (CNW Group/Merck Canada Inc.)". Image available at: http://photos.newswire.ca/images/download/20140403_C8568_PHOTO_EN_38809.jpg
SOURCE: Merck Canada Inc.
For further information:
NATIONAL Public Relations